Capricor Therapeutics, NIH collaborate for trial of StealthX vaccine

Capricor Therapeutics announced that Capricor’s proprietary StealthX exosome-based multivalent vaccine for the prevention of SARS-CoV-2 has been selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines providing broader and more durable protection for COVID-19. As part of Project NextGen, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, will conduct a Phase 1 clinical study with Capricor’s StealthX vaccine, subject to regulatory approval. NIAID’s Division of Microbiology and Infectious Diseases would oversee the study.